Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results …
SA Springer, A Di Paola, MM Azar… - JAIDS Journal of …, 2018 - journals.lww.com
Objective: To determine whether extended-release naltrexone (XR-NTX) would improve or
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results …
SA Springer, A Di Paola, R Barbour… - JAIDS Journal of …, 2018 - journals.lww.com
Objective: To determine whether extended-release naltrexone (XR-NTX) would improve or
maintain viral suppression (VS) among incarcerated individuals with HIV and alcohol use …
maintain viral suppression (VS) among incarcerated individuals with HIV and alcohol use …
Hiv clinic‐based extended‐release naltrexone versus treatment as usual for people with hiv and opioid use disorder: A non‐blinded, randomized non‐inferiority trial
PT Korthuis, RR Cook, PJ Lum, EN Waddell… - …, 2022 - Wiley Online Library
Background and aim Opioid agonist medications for treatment of opioid use disorder (OUD)
can improve human immunodeficiency virus (HIV) outcomes and reduce opioid use. We …
can improve human immunodeficiency virus (HIV) outcomes and reduce opioid use. We …
[HTML][HTML] Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and …
A Di Paola, T Lincoln, DJ Skiest, M Desabrais… - Contemporary clinical …, 2014 - Elsevier
Background People with opioid dependence and HIV are concentrated within criminal
justice settings (CJS). Upon release, however, drug relapse is common and contributes to …
justice settings (CJS). Upon release, however, drug relapse is common and contributes to …
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
SA Springer, FL Altice, SE Brown, A Di Paola - Drug and Alcohol …, 2015 - Elsevier
Background The acceptability of and retention on extended-release naltrexone (XR-NTX),
an FDA-approved medication for the treatment of alcohol and opioid use disorders, among …
an FDA-approved medication for the treatment of alcohol and opioid use disorders, among …
Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial
PT Korthuis, PJ Lum, P Vergara‐Rodriguez… - …, 2017 - Wiley Online Library
Background and aims HIV‐infected people with substance use disorders are least likely to
benefit from advances in HIV treatment. Integration of extended‐release naltrexone (XR …
benefit from advances in HIV treatment. Integration of extended‐release naltrexone (XR …
Medications for treatment of opioid use disorder among persons living with HIV
L Fanucchi, SA Springer, PT Korthuis - Current HIV/AIDS Reports, 2019 - Springer
Abstract Purpose of Review Recent HIV outbreaks have occurred as a result of the current
US opioid epidemic. Providing medications for opioid use disorder (MOUD) with methadone …
US opioid epidemic. Providing medications for opioid use disorder (MOUD) with methadone …
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
SA Springer, A Di Paola, MM Azar, R Barbour… - Drug and alcohol …, 2017 - Elsevier
Abstract Background Alcohol use disorders (AUDs) are highly prevalent among persons
living with HIV (PLH) within the criminal justice system (CJS). Extended-release naltrexone …
living with HIV (PLH) within the criminal justice system (CJS). Extended-release naltrexone …
[HTML][HTML] Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners
SA Springer, J Qiu, AS Saber-Tehrani, FL Altice - PloS one, 2012 - journals.plos.org
Introduction HIV-infected prisoners lose viral suppression within the 12 weeks after release
to the community. This prospective study evaluates the use of buprenorphine/naloxone …
to the community. This prospective study evaluates the use of buprenorphine/naloxone …
Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: a randomized-controlled trial
EJ Edelman, BA Moore, SR Holt, N Hansen… - AIDS and Behavior, 2019 - Springer
We sought to test the efficacy of extended-release naltrexone (XR-NTX) on HIV-related and
drinking outcomes. From April 2011-February 2015, we conducted a 4-site randomized …
drinking outcomes. From April 2011-February 2015, we conducted a 4-site randomized …